Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.94 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL8065018 | 0.97 | CA4 (0.90) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL29802314 | 0.97 | CA4 (0.90) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL276988 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL9405236 | 0.97 | CA4 (0.89) | CA4CASP1ALDH1A1 | |
| Citric Acid SCHEMBL3657 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL2235356 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL715802 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL66313 | 0.97 | CA4 (0.89) | CA4CASP1ALDH1A1 | |
| Citric Acid SCHEMBL11060179 | 0.97 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL9134521 | 0.97 | CA4 (0.89) | CA4CASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 875 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748924-A2 | PERFUSION CULTURE METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-27 | — | — | EP | claimed |
| US-12558333-B2 | Agent for ameliorating and/or preventing sickle cell disease | THE UNIVERSITY OF TOKYO (JP) | 2026-02-24 | — | — | US | claimed |
| US-12558332-B2 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor | SBI PHARMACEUTICALS CO., LTD. (JP) | 2026-02-24 | — | — | US | claimed |
| US-20250262179-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING AUTOIMMUNE DISEASES | SBI PHARMACEUTICALS CO., LTD. (JP) | 2025-08-21 | — | — | US | claimed |
| CN-119499235-B | Pharmaceutical composition of sodium ferrous citrate and preparation method thereof | 北京柏雅联合药物研究所有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-20250163487-A1 | PERFUSION CULTURE METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-22 | — | — | US | claimed |
| CN-119547840-A | Functional dietary fiber gel soft sweet and preparation method thereof | 艾兰得营养品泰州有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-119499235-A | Pharmaceutical composition of sodium ferrous citrate and preparation method thereof | 北京柏雅联合药物研究所有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-116063173-B | Ferrous sodium citrate and preparation method thereof | 北京柏雅联合药物研究所有限公司 | 2025-02-11 | — | — | CN | claimed |
| EP-4487843-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING AUTOIMMUNE DISEASES | National Center for Child Health and Development (JP) | 2025-01-08 | — | — | EP | claimed |
| US-5700453-A | COMPRISING SALT OR HYDROXIDE OF DI- OR TRIVALENT METAL, WATER SOLUBLE ALGINATE, RED OR ORANGE LAKE COLOR HAVING CARBOXYLATE SALT GROUP, OIL COMPONENT HAVING LIQUID APPEARANCE; NON-DRYING, COLORFAST | KANEBO, LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0585981-B1 | Lipcolor composition | KANEBO LTD (JP) | 1997-06-18 | — | — | EP | claimed |
| US-5520725-A | Dental glass ionomer cement composition | GC CORPORATION (JP) | 1996-05-28 | — | — | US | claimed |
| US-5447732-A | Polyglutamic acid and minerals | AJINOMOTO CO., INC. (JP) | 1995-09-05 | — | — | US | claimed |
| EP-0585981-A1 | Lipcolor composition | KANEBO LTD. (JP) | 1994-03-09 | — | — | EP | claimed |
| EP-0401377-B1 | IRON-CONTAINING PREPARATION FOR USE AS NMR CONTRAST MEDIUM | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-15 | — | — | EP | claimed |
| US-5174987-A | Administering orally the contrast media consists of sodium carbonate or bicarbonate, ferrous or ferric compounds, and a neutralizing agent; easy to drink; clear and accurate contrast imaging of inner organs | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-29 | — | — | US | claimed |
| US-5160728-A | Sodium carbonate, neutralization, potassium carbonate | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-03 | — | — | US | claimed |
| US-5087442-A | Containing iron citrate compound, sodium carbonate and/or bicarbonate, acid neutralizing agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | claimed |
| EP-0401377-A1 | IRON-CONTAINING PREPARATION FOR USE AS NMR CONTRAST MEDIUM | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558333-B2 | Agent for ameliorating and/or preventing sickle cell disease | HBB, HBZ, HBG1 | CA4 1259/4885CASP1 3127/4885FFAR3 3846/4885 |
| US-20250262179-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING AUTOIMMUNE DISEASES | IL5, MTX1, HLA-DRB1 | CA4 1992/4885CASP1 376/4885FFAR3 1392/4885 |
| US-12558332-B2 | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor | CD274, PDCD1, PDCD1LG2 | CA4 3463/4885CASP1 400/4885FFAR3 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.